Newsroom

When cancer comes back: Drug for mantle-cell lymphoma gives patients more time

March 30, 2016



A study recently published in The Lancet shows that a new treatment for an aggressive form of blood cancer can significantly extend patients’ lifespans after relapse. This international randomized Phase 3 clinical trial of 280 patients, co-authored by Dr. Isabelle Bence-Bruckler, is the first to compare the two targeted treatments for mantle-cell lymphoma (MCL) in cases where the cancer relapses after standard chemotherapy treatments. This study found that patients taking the newer treatment called ibrutinib had significantly better survival (14.6 months) compared with those taking intravenous temsirolimus (6.2 months). While both treatments had side effects, patients taking ibrutinib were less likely to stop the treatment because of them. Ibrutinib is approved in Canada for certain uses, but public funding for mantle cell lymphoma is yet to be secured.

Co-authors: Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S.

Funders: Janssen Research & Development

About The Ottawa Hospital


The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care.

About the University of Ottawa


The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe. www.uottawa.ca

For further information, please contact


Amelia Buchanan
Senior Communication Specialist
Ottawa Hospital Research Institute
Office: 613-798-5555 x 73687
Cell: 613-297-8315
ambuchanan@ohri.ca